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Evaluation of Mixed Chimerism by In Vitro Amplification of Dinucleotide Repeat Sequences Using the Polymerase Chain Reaction
By M. Lawler 
LLOGENEIC bone marrow transplantation (BMT) is
A now a successful modality of therapy for many patients with leukemia or aplastic anaemia.' Successful outcome has been associated with a state of stable chimerism, ie, all marrow being of donor origin in the post-BMT state. 2 Traditional methods used to evaluate the degree of chimerism post BMT have been protein or red blood cell (RBC) polymorphisms or karyotyping.'.' More recently it has been shown that DNA studies using restriction fragment length polymorphisms (RFLPs) and Southern blotting techniques can be used to distinguish between donor and recipient cells post BMT,' and this technology is now recognized as a highly sensitive measurement of degrees of chimerism.8-'" Using these more sensitive techniques, mixed chimerism (MC), ie, the stable coexistence of donor and recipient cells post BMT, has been shown to be a more common phenomenon than was previously suggested and does not necessarily signify impending graft failure or leukemic relapse.'o," Using RFLP analysis, MC can be detected at levels approaching lo%.'' Use of even more sensitive techniques may allow the accurate quantitation of a mixed population of cells at or below the 1% level. Previously we have reported a rapid technique to detect minor cell populations in sex mismatched tran~p1ants.I~ The assay system used was analysis but PCR of microsatellites or Y chromosomal material could be used successfully to assess the origin of cells in this archival material. Cytogenetic analysis was possible in 17 patients and M C was detected in three patients. Twelve patients received T-cell-depleted marrow and showed a high incidence of M C as revealed by PCR (>80%). Twenty patients received unmanipulated marrow, and while the incidence of MC was lower (44%). this was a high percentage when compared with other studies. Once M C was detected, the percentages of recipient cells tended t o increase. However, in patients exhibiting M C who subsequently relapsed, this increase was relatively sudden. The overall level of recipient cells in the group of M C patients who subsequently relapsed was higher than in those who exhibited stable MC. based on the polymerase chain reaction (PCR), a technique that permits rapid accumulation of specific genetic material from a target template by using an in vitro amplification rea~ti0n.l~
To apply this assay to all transplant situations, we have made use of highly polymorphic neutral variation in the human genome that has been shown recently by PCR.15,'6 This variation occurs in repetitive tandem blocks of the simple sequence (dC -dA)n:(dG -dT)n. This simple dinucleotide repeat is present at a copy number of approximately 50,000 dispersed throughout the human genome.I6 Tandem repetitive blocks differ in the number of their repeats between individuals. This variation can be shown by PCR. Primers are designed that complement single copy sequences which flank the simple sequence blocks, and subsequent electrophoresis then shows size differences between individuals. These polymorphic simple sequence blocks are termed microsatellites as they are small in size (n = 15 to 30) and microsatellites at a single locus can differ by as little as two base pairs.
Previously we have assessed the usefulness of microsatellites as markers of engraftment by typing a group of 32 donor-recipient pairs using a panel of seven microsatellites." Subsequently, Roth et all8 have shown that PCR of fragment length polymorphisms (PCR-FLP) is a highly sensitive method for assessment of chimerism post BMT. We have also used PCR-FLP in the assessment of chimerism using a highly informative length polymorphism at the APOB locus on chromosome 2." In the present study a panel of seven microsatellites and three Y-specific sequences have been used to assess chimerism in a longitudinal study on 32 patients after BMT. The conditioning regimen consisted of cyclophosphamide (60 mgkgid X 2) followed by single fraction total body irradiation (TBI) delivered by an 8-mV linear accelerator at 18 cGy/min to a total dose of 7.5 Gy. UPN 001286 received 9.5 Gy at a dose of 4 cGy/min and UPN 003-89 received fractionated TBI at 2 Gy per fraction for three fractions and cyclophosphamide at 5 mgikgld x 4. Six patients received busulphan (4.0 mgkg/d for 4 days) followed by cyclophosphamide (60 m a g i d x 2). T-cell depletion was performed on 12 patients using monoclonal antibodies and baby rabbit complement as previously described.w All patients received irradiated leukocyte-depleted blood products throughout the course of their BMT.
Material for PCR was prepared as follows. Fifty microliters of peripheral blood or bone marrow aspirates was suspended in an equal volume of ddH20 and centrifuged for 1 minute to pellet white blood cells. These cells were resuspended in the same volume of ddH20 and heated at 94°C for 5 minutes to lyse cells (material from stored slides was scraped into 50 JLL of ddH2O using a sterile scalpel blade and heated as described above).
Transplant conditioning regimen.

PCR analysis.
Cellular debris was removed by centrifugation and 1 to 5 JLL of supernatant was used in each PCR.
Y-specific amplification was as previously de~cribed,'~ except a panel of three primer pairs was used to detect Y-chromosomal material, and cycling parameter times were as follows: 94"C, 20 seconds; 55"C, 30 seconds; and 72"C, 1 minute for 30 cycles.
While microsatellite amplification was initially as described," subsequent modifications provided more interpretable data. Lysed supernatant, 1 to 5 mL, was added to a reaction mix containing 16 mmoVL (NH,),SO,, 66 mmol/L Tris-HC1 pH 8.9, 5 to 8 mmol/L MgCI,, 200 pmol/L each of dGTP, dATP, and dTTP, 2 to 10 bmol/L dCTP, and 1 FCi a 32PdCTP at 4,000 Ci/mmol. This ammonium-based assay buffer is in regular use in our laboratory in the multiplex PCR protocol for analysis of Duchenne muscular dystrophy (DMD) deletions,2' and we felt it would be of use in this study especially in the amplification of multiple microsatellites. Samples were overlaid with liquid paraffin and heated to 94°C for 7 minutes. Twenty-five picomoles of each oligonucleotide were mixed with 2 to 5 U of Taq polymerase (Cetus, Emeryville, CA) and made up to 5 pL in Taq dilution buffer. This mixture was added to the reaction mix at 80°C. This addition of enzyme and oligonucleotides at an elevated temperature following denaturation of the template yielded more specific product, presumably because nonspecific priming can occur at lower temperatures as the thermal cycler approaches the melting temperature. The use of the Cetus enzyme is recommended; other enzymes tested showed use only. Samples were processed through 30 cycles of amplification with the following temperature parameters: 94°C. 1 minute; 50 to 55°C. 1 minute; 72°C. 1 minute, with a I-second step extension on each cycle. Each primer pair was first tested for its magnesium (Mg") optima by performing a magnesium titration profile assay. Sample DNA was amplified in PCR buffer containing 3, 5, 6, 7. 8, and 10 mmol/L MgCI, to best assess Mg' concentration with the strongest amplification signal and the least background. Various primer sets were combined based on their Mg" optima and size separation of amplification products. Thus, several microsatellites could be typed simultaneously (multiple microsatellite amplification, see Fig  1 ) . When multiplex amplification was performed, reactions were allowed to proceed for 10 to 15 cycles before addition of a "P dCTP.
of the sample volume was taken and mixed with an equal volume of formamide sample buffer, heated to 94°C for 3 minutes, and electrophoresed through preheated standard denaturing 8% polyacrylamide sequencing gels. Gels were dried down and subjected to autoradiography with intensifying screens at -70°C for 4 to 24 hours. All primers used in this study were synthesized on an Applied Biosystems 391 PCR MATE DNA synthesizer (Applied Biosystems, Foster City, CA) and purified through OPC columns (ABS). A list of all primers used, their Mg" optima, and informativeness is shown in Table 2 .
As PCR is sensitive to contamination, several precautions were taken to avoid false positives, especially in relation to the amplification of slide material. In all PCRs, care was taken to include several negative controls, and in several cases buffers were incubated with restriction enzymes that cut within the amplified fragment before amplification to ensure that any contaminating material would not act as a template for PCR, eg. Pvu I1 for ApoA2, Acc I for Sst. Kpn I for IGF 1, and Hpa II for RHO. Restriction enzymes were then heat killed to ensure that they did not interfere with PCR. As all experiments were performed by one operator, material from that individual was amplified and the microsatellite pattern compared with that of donor or recipient and posttransplant samples to exclude contamination by the operator. Material from the operator was obtained by pelleting cells from a saline mouthwash and lysing by the boiling method as described above.
Cytogenetics. Where relevant, bone marrow aspirates were performed at varying time intervals post BMT. Karyotyping was performed using standard techniques. A mean of 26 metaphases was analyzed per sample. The Y chromosome was detected using quinacrine banding.
Definitions. Patients who exhibited complete donor hematopoiesis with all markers tested at all times were defined as donor chimeras. Patients who exhibited mixed populations of donor and host cells on more than one occasion with at least three different markers after day 45 or when the recipient was transfusion independent (whichever was the earliest) were considered to exhibit MC. Patients with mixed populationsof cells within 4 weeks of relapse were not considered to have stable MC. This was done to exclude patients with neoplastic recipient cells from the group of patients who exhibited stable MC. All sequences are written 5' to 3'. Mg optima indicates the range of concentrations at which a specific product is produced.
*PIC, polymorphism information content. A measure of the informativeness of a particular probe. A PIC value of l implies that a probe is informative for all individuals, while a PIC value of 0 implies that a probe is monomorphic.
Statistics. Regression analysis was performed using an unweighted least-squares linear regression model. Differences in regression coefficients were calculated by an analysis of variance and significance was determined using an F-test. Otherwise, significance testing was performed using Fisher's exact t-test and appropriate tables.
RESULTS
Evaluation of microsatellite and Y-specific amplification in the typing of donor-recipientpairs. Initially, nine microsatellite markers were tested for polymorphic variation in 32 donor-recipient pairs. However, two of these markers were not used in subsequent assessment of chimerism after BMT. Informative polymorphisms with the remaining seven markers were found in 30 of 32 pairs, while two pairs (UPNs 00888 and 001689) were identical twin pairs and showed no informative polymorphisms with all markers tested.
The inclusion of syngeneic pairs was done deliberately to test the validity of the polymorphisms observed and to rule out contamination by the operator. Also, while in practice prescreening of the donor and recipient with each microsatellite marker allows us to select informative polymorphisms, we also performed PCR on noninformative posttransplant samples as an additional check against contamination. No new alleles were seen after 45 days posttransplant, although several were seen at earlier times posttransplant.
The microsatellite markers used were: ApoA2, a microsatellite at the apolipoprotein A2 locus on the long arm of chromosome 1; ApoC2, a microsatellite at the apolipoprotein C2 locus on chromosome 19; IGFI, a microsatellite at the insulin growth factor locus on the long arm of chromosome 12; SST, a microsatellite at the somatostatin locus on the long arm of chromosome 3; RHO, a microsatellite at the rhodopsin locus also on chromosome 3; Mfd8, a microsatellite at an anonymous locus, and CAR I, a microsatellite at the cardiac actin gene locus on the long arm of chromosome 15. The degree of polymorphism that these microsatellites exhibited in our patient population is shown in Table 3 . A highly informative microsatellite that we have used is ApoA2, and a donor-recipient profile for this microsatellite is shown in Fig 2 .
Magnesium profiles were performed on all microsatellites to assess optimum Mg2+ concentrations for each primer pair, as we and others" have found that different primer pairs can have different and sometimes very specific magnesium requirements. Microsatellite primers that showed identical or overlapping Mg2+ optima were then assessed for selective coamplification in the same tube. This allowed different microsatellites to be typed simultaneously, provided that their allele size range was nonoverlapping.
Eighteen of the 32 D/R pairs were sex mismatched, and so the presence or absence of the Y chromosome could also be used as an informative polymorphism. A panel of three specific primer pairs was used to detect the presence of male cells.
Assessment of chimerism using Y-specific and microsatellite markers. Using a combination of microsatellite and Y-specific markers, chimerism was assessed in 32 patients who received BMT in a 5-year period from November 1984 to December 1989. Samples were examined as early as day 17.
MC was documented in 18 of 32 patients (56%). Levels of recipient cells ranged from 0.5% to 90%. MC was detected as early as day 29 (UPN 001288), while persistant stable MC was observed as long as 678 days post BMT (UPN 00487). Examples of MC are shown in Fig 3 (A through D) . Twelve patients have maintained 100% donor hematopoiesis as documented by PCR markers in our study while two patients (UPNs 001689 and 00888) who were twins were not informative with any markers tested. , h of the reaction was taken, primers and excess dNTPs removed by spin dialysis, and the sample was then reamplified for a further 30 cycles under conditlons as described in Materials and Methods) using the ApoC2 primers and run on 4% agarose gels, which were stained with ethidium bromide t o reveal amplified fragments. (0) is heterozygous for the alleles exhibited by donor and recipient. However, this patient is also informative for ApoA2, ApoC2, and CAR, and the only partial overlap involves CAR. As ApoA2 and ApoC2 do not show any alleles in common between operator and either donor or recipient (data not shown), we believe that the possibility of operator contamination in the analysis of this patient is excluded. Analysis of samples s h o w I C as an early indicator of subsaquent recipient reamergence and relapse. These samples were also used in multiple microsatellite ampltfication (Fig   1) .
use only. Cytogenetic analysis was performed in 17 patients post BMT using the Y chromosome or the Philadelphia chromosome as a discriminating marker. MC was detccted in three patients (17.6%). MC was documented in patients with diffcrent types of leukemia and with aplastic anemia; four of six patients transplanted for chronic granulocytic leukemia (CGL), two of nine patients transplanted for acute myeloid leukemia (AML), all three patients with acute promyelocytic leukemia (APML), six of scvcn patients with acute lymphoblastic leukemia (ALL), a single patient with Fanconi's anemia (FA), and two of three patients with severe aplastic anemia (SAA).
MC and T-cell depletion. Twelve patients underwent T-cell depletion of donor marrow before BMT ( Table 1) and 10 showed evidence of MC after BMT ( Table 4) . Twenty paticnts received unmanipulated bone marrow and eight of thesc patients subsequently exhibited MC (Table  4) . Thus, thc probability of developing MC was higher in T-cell-depleted paticnts than in patients in which no T-cell deplction was performcd (P = .02).
In T-cell-deplctcd patients MC was always detected using PCR, and in only one patient (UPN 001086) did karyotypic analysis detect residual recipient cells at the same time as PCR. This patient exhibited 100% recipient hematopoiesis as demonstrated by PCR and cytogenetics indicating autologous recovery. In non T-cell-dcpleted patients, one recipient (UPN 00988) was shown to be a mixed chimera by PCR and cytogenetics simultaneously ( Table 4) . A second patient (UPN 001288) was found subsequently to have rccipient cells by cytogenetics at day 78 post BMT, but still exhibited a donor karyotype at day 36 post BMT whcn PCR first detected MC ( Table 4 ). In the rcmaining six patients, MC was only detectcd by PCR.
Of the 18 patients who exhibited MC, five relapsed and died, one is alive in relapse, two had graft failure, two died of graft-versus-host disease (GVHD)-related problcms, one developed AML after transplantation for SAA, and seven arc alive and well following transplantation, including one patient who showed autologous recovery. No patient relapsed, rejected hisher graft, or died without some evidence of MC.
Microsatellite markcrs allowed direct analysis of the degree of MC. Dilution experiments indicated that residual host DNA can easily be detected at the 1% to 5% levels (Fig 4) . while with some microsatellites (ApoA2, ApoC2) this figure can be rcduced to 0.1% to 0.5% (data not shown). Levels of MC were shown to vary widely in our study with a definite increase in MC over time (Fig 5) . Patients can have progressively higher levels of recipient cells (eg, UPN 00688: day 72, 2%; day 519, 25%) or they can exhibit persistent low levels of MC (eg, UPN 001387: day 182, 1%; day 620, 1%). Patients can show sudden increases in levels of MC early post BMT (eg. UPN 001288: day 29.4%; day 141,81% [Fig3A]) or they can show such elevations at later times post BMT (eg, UPN 00687: day 20,0%; day 332.30%; day 663,5596). As donors and recipients showed alleles that differed by greater than 10 bases, it was possible to analyze this transplant by ethidium bromide staining without the use of radioactivity using the microsatellitc APOC2 ( Fig  3B) . This analysis was also possible in several other transplants (data not shown).
Howcver, patients who exhibit MC and are in remission and patients who exhibit MC and subsequently relapse tend to fall into two different groups. Analysis of the regression coefficients associated with the slope of each curvc (Fig 5 ) show a significant difference betwecn paticnts in remission and thosc who subsequently relapse (P < .005). Patients who subsequently rclapse show a higher and more rapid increase in recipient cclls than those patients exhibiting MC in remission.
While this is a general trend associated with the data in this study, there are some exceptions. UPN 001087 was MC and subsequent outcome.
Lewls of recipient cells in patients exhibiting MC.
use only.
For personal at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From found to have 2% recipient cclls at day 71, 7% recipient cells at day 147, and subsequently was found to have a latc graft rejection that caused thc dcath of thc patient (Fig3C). UPN 00389 showed moderate levels of MC (14% to 29%), but while the levcl of MC increased from 14% at day 39 to 29% at day 102, it subsequently dccrcascd to 18% at day 160. This patient then devclopcd scverc GVHD and died of associated complications. Eleven patients yielded ambiguous results. Three patients (UPNs 00688, 001088, and 00289, sce Fig 3E) exhibitcd new alleles with certain microsatcllitc markcr(s) that were not dctected in cithcr donor or recipient cells before transplant. Seven patients (UPNs 00489, 001386, 00588, 001086, 00689, 001387, and 00487) were found to bc mixed chimeras by one or two microsatcllites, whereas thc majority of microsatellites indicated donor or recipient chimeras. In three of these sevcn patients (UPNs 001387, 00588, and 00487). levels of MC wcre very low ( < 1%) and were detectcd using ApoA2 and ApoC2, thc most sensitivc of thc microsatellites. One patient (UPN 00787) had evidcnce of both new and mixed populations of cclls at different times post BMT. Apart from the three c a w of very low MC, which we feel reflect the higher detection sensitivities associatcd with APOA2 and APOC2, all other chimeras wcrc observed as carly events ( <42 days posttransplant) and were transient in their nature. Levels of new or transient mixed populations of cclls ranged from 1.6% to 50% (mean = 8.9%).
All microsatcllitc markers except RHO dctected at lcast one ncw or existing transient cell population. Nonc of these carly events were included as evidcncc of MC as they did not satisfy our criteria for MC in this study.
Transient chimeras.
DISCUSSION
We rcport a novel and exquisitivcly sensitive method for the assessment of chimerism following allogcncic BMT and the application of this method to thc asscssmcnt of MC in a longitudinal study on 32 patients. The method involves the development of microsatellites as markers of engraftment using the PCR.
Microsatellites are simple tandem repeats of the 2-bp sequence (dC:dA):(dG:dT) that vary in their repeat number between individuals. Using PCR, microsatellites can be used to distinguish between donor and recipient cells after allogeneic BMT. A panel of these markers is described. The panel contains microsatellites from different regions of the human genome. Conditions have been defined that permit the coamplification of two or more microsatellites, allowing several microsatellites to be typed simultaneously in the same test tube. The random distribution of these microsatellites allows chimerism to be assessed even in patients where genetic material is lost, eg, in myelodysplasia where there can be multiple deletions including 5q-, -7, and -1lq. Microsatellites are highly polymorphic, especially if a panel of different microsatellites is used, and this facilitates the monitoring of the vast majority of donor-recipient pairs efficiently. PCR dispenses with the need for the laborious and time-consuming techniques used in RFLP analysis. Recently, minisatellites have been used as markers of engraftmenLZ3 However, high stringency conditions are required to show the correct banding pattern and total minisatellite profiles can be quite complicated, sometimes only allowing MC to be determined at the 10% to 25% sensitivity Microsatellites are highly informative, permit chimerism to be assessed quickly, and allow MC to be detected at or below the 1% level.
MC was assessed in 32 patients using microsatellites and Y-specific amplification over a period ranging from 2 weeks to 5 years. Although we established MC as a definite finding as early as day 29, we looked for MC as early as day 17 and it was observed in two patients (UPNs 001487 and 00589) at day 20. In these two patients further samples were not obtained due to premature death. Roth et all8 have shown that PCR can detect MC as early as day 7, even when leukocyte counts are as low as 20 mm3. MC was detected in 18 patients (56%), whereas 12 patients (37.5%) showed complete donor hematopoiesis. Karyotypic analysis was possible in 17 patients and MC was detected in three cases (17.6%). PCR detected MC more frequently than cytogenetics. PCR also detected an overall higher level of recipient cells than cytogenetics. The more frequent detection of MC by PCR displays not only the exquisite sensitivity of the technique, but it also reflects the fact that PCR analysis involves DNA from all nucleated cells whereas cytogenetic analysis merely concentrates on the cells that are actively dividing. Furthermore, stimulation of these dividing cells may favor the donor or recipient component in vitro, thus distorting the true level of MC in a study.
In this study eight patients exhibited abnormal or nonconfirmed alleles at early times post BMT. The transient nature of these alleles excluded somatic mutation. Although PCR has recently been criticized as being prone to contamination," these alleles were only observed in the first 45 days post BMT and never later. Such a nonrandom distribution of these new alleles militates against contamination. As there was only one operator in these experiments, the microsatellite profile of the operator was compared with the posttransplant samples to see if the presence of operator DNA could be correllated with these new alleles. Only two examples occurred in which the operator shared alleles with the recipient, and in only one case did the recipient and operator profiles match at both loci. Analysis of the source of material revealed that both aspirates and stored slide material showed new alleles, thus eliminating the possibility that contamination of slide material was the source of these new alleles. Examination of the patients' charts indicated that all of these patients were transfusion use only.
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